Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of pegozafermin in MASH with fibrosis
MOH_2024-07-01_013382Phase 3Recruiting
- Sponsor
- 89bio
- Start
- Jun 2024
- Modality
- Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pegozafermin in metabolic dysfunction-associated steatohepatitis (MASH) (3 arms), sponsored by 89bio. Primary endpoint: Composite clinical outcome risk reduction. Started Jun 2024; status: recruiting.
02
Drugs
pegozafermin
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on MOH_2024-07-01_013382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-07-01_013382.